BioMarin's (BMRN) Pegvaliase Likely to Receive FDA Approval Amid Recent Mixed Data - Wedbush
Tweet Send to a Friend
Wedbush reaffirms BioMarin Pharmaceuticals (Nasdaq: BMRN) at Neutral with a price target of $108 after the company reported that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
